Nanoparticles in Ocular Drug Delivery Systems

Almeida, Hugo; Silva, Ana Catarina

doi:10.3390/pharmaceutics15061675

Cited by 3 publications

(2 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hybrid nanoparticles are combinations of different materials, such as polymers and metallic nanoparticles, that can combine different features, such as the ability to release drugs and image eye structures. Biological nanomaterials use biological nanoparticles, such as proteins or lipids, which minimizes the risk of allergic reactions and improves biocompatibility [106][107][108][109][110].…”

Section: Ocular Nanosystemsmentioning

confidence: 99%

Available Therapeutic Options for Corneal Neovascularization: A Review

Drzyzga,

Śpiewak,

Dorecka

et al. 2024

IJMS

View full text Add to dashboard Cite

Corneal neovascularization can impair vision and result in a poor quality of life. The pathogenesis involves a complex interplay of angiogenic factors, notably vascular endothelial growth factor (VEGF). This review provides a comprehensive overview of potential therapies for corneal neovascularization, covering tissue inhibitors of metalloproteinases (TIMPs), transforming growth factor beta (TGF-β) inhibitors, interleukin-1L receptor antagonist (IL-1 Ra), nitric oxide synthase (NOS) isoforms, galectin-3 inhibitors, retinal pigment epithelium-derived factor (PEDF), platelet-derived growth factor (PDGF) receptor inhibitors, and surgical treatments. Conventional treatments include anti-VEGF therapy and laser interventions, while emerging therapies such as immunosuppressive drugs (cyclosporine and rapamycin) have been explored. Losartan and decorin are potential antifibrotic agents that mitigate TGF-β-induced fibrosis. Ocular nanosystems are innovative drug-delivery platforms that facilitate the targeted release of therapeutic agents. Gene therapies, such as small interfering RNA and antisense oligonucleotides, are promising approaches for selectively inhibiting angiogenesis-related gene expression. Aganirsen is efficacious in reducing the corneal neovascularization area without significant adverse effects. These multifaceted approaches underscore the corneal neovascularization management complexity and highlight ideas for enhancing therapeutic outcomes. Furthermore, the importance of combination therapies and the need for further research to develop specific inhibitors while considering their therapeutic efficacy and potential adverse effects are discussed.

show abstract

Section: Ocular Nanosystemsmentioning

confidence: 99%

Available Therapeutic Options for Corneal Neovascularization: A Review

Drzyzga,

Śpiewak,

Dorecka

et al. 2024

IJMS

View full text Add to dashboard Cite

show abstract

“…Faculty of Pharmacy, Univ Coimbra-University of Coimbra, CIBB, Pólo das Ciências da Saúde, Azinhaga de Santa Comba, 3000-548 Coimbra, Portugal * Correspondence: anacatsil@gmail.com Among the different types of nanosystems that have been investigated for therapeutic use, lipid-based ones are the most explored, as they have advantages over non-lipid nanosystems, especially for improving the transport and efficacy of drugs through different routes of administration, such as ocular, cutaneous, intranasal, and intravenous [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18].…”

mentioning

confidence: 99%